Skip to main content
. Author manuscript; available in PMC: 2012 Apr 1.
Published in final edited form as: Semin Radiat Oncol. 2011 Apr;21(2):80–87. doi: 10.1016/j.semradonc.2010.10.003

Figure 6.

Figure 6

Schematic drawing of the theranostic approach. The diagnostic particle consists of a diagnostic moiety and a coating, modified with a nuclide (green), targeting an antigen (brown), here deposited between the tumor cells. Imaging is performed with MRI and PET. The particle can carry a payload drug (red) that is released in the tumor creating a theranostic agent, allowing for imaging and therapy of the tumor.